Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Neil William AubuchonChief Commercial Officer | Viking TherapeuticsVKTX | Open-market buy | 03/10 | 03/10 | 4,475 sh | $33.50 | $149,912.5 | No record |
Viking TherapeuticsVKTX | Open-market sale | 01/05 | 01/05 | 57,661 sh4 trades | $32.90avg. | $1,897,129.3 | −23.3% | |
Viking TherapeuticsVKTX | Open-market sale | 01/05 | 01/05 | 233,409 sh4 trades | $32.96avg. | $7,692,305.4 | −8.5% | |
Viking TherapeuticsVKTX | Open-market sale | 01/05 | 01/05 | 57,661 sh4 trades | $32.97avg. | $1,901,274.69 | −12.4% | |
Foehr Matthew W.Director | Viking TherapeuticsVKTX | Open-market sale | 01/02 | 01/05 | 16,000 sh | $35.11 | $561,760 | −10.8% |
Greg ZanteCFO | Viking TherapeuticsVKTX | Open-market sale | 25/10/28 | 25/10/28 | 6,185 sh | $35.00 | $216,475 | −3.4% |
Brian LianPresident & CEO | Viking TherapeuticsVKTX | Open-market sale | 25/10/28 | 25/10/28 | 38,989 sh | $35.01 | $1,365,004.89 | −1.6% |
Viking TherapeuticsVKTX | Open-market sale | 25/10/28 | 25/10/28 | 6,185 sh | $35.00 | $216,475 | −1.6% | |
Charles A. Rowland Jr.Director | Viking TherapeuticsVKTX | Open-market sale | 25/10/27 | 25/10/28 | 60,000 sh | $35.57 | $2,134,200 | −66.7% |
Greg ZanteCFO | Viking TherapeuticsVKTX | Open-market sale | 25/07/03 | 25/07/03 | 4,266 sh | $27.76 | $118,424.16 | −2.5% |
Brian LianPresident & CEO | Viking TherapeuticsVKTX | Open-market sale | 25/07/03 | 25/07/03 | 26,889 sh | $27.80 | $747,514.2 | −1.1% |
Viking TherapeuticsVKTX | Open-market sale | 25/07/03 | 25/07/03 | 4,266 sh | $27.77 | $118,466.82 | −1.1% | |
Sarah Kathryn RouanDirector | Viking TherapeuticsVKTX | Open-market buyAmendment | 25/03/31 | 25/04/08 | 1,240 sh | $24.15 | $29,946 | No record |
Sarah Kathryn RouanDirector | Viking TherapeuticsVKTX | Open-market buy | 25/03/31 | 25/04/02 | 1,240 sh | $24.15 | $29,946 | No record |
Viking TherapeuticsVKTX | Open-market sale | 25/01/06 | 25/01/06 | 50,309 sh2 trades | $42.75avg. | $2,150,652.21 | −23.3% | |
Viking TherapeuticsVKTX | Open-market sale | 25/01/06 | 25/01/06 | 194,490 sh2 trades | $42.74avg. | $8,312,993.2 | −7.6% | |
Viking TherapeuticsVKTX | Open-market sale | 25/01/06 | 25/01/06 | 54,215 sh2 trades | $42.75avg. | $2,317,651.35 | −12.7% | |
Lawson MacartneyDirector | Viking TherapeuticsVKTX | Open-market sale | 24/11/08 | 24/11/08 | 2,000 sh | $68.67 | $137,340 | −4.0% |
Viking TherapeuticsVKTX | Open-market sale10b5-1 plan | 24/10/28 | 24/10/28 | 131,687 sh8 trades | $76.62avg. | $10,089,306.42 | −46.9% | |
J. Matthew SingletonDirector | Viking TherapeuticsVKTX | Open-market sale10b5-1 plan | 24/10/25 | 24/10/25 | 16,000 sh | $79.50 | $1,272,000 | −62.7% |